The document discusses the implications of a 2011 European court ruling that banned patents on procedures involving human embryonic stem cells and any downstream products using these cell lines. This ruling pulls funding from developing stem cell therapies. However, the ruling highlights that intellectual property value can still be achieved through other stem cell types, in non-European territories, and from associated technologies. The document provides examples of companies developing stem cell therapies through these alternative approaches and focuses on enabling technologies, such as delivery devices, that provide opportunities to secure intellectual property.